A Post-Treatment Evaluation of Total IgE, CRP and Blood Count Parameters of Children With Asthma

Year 2013, Volume: 15 Issue: 1, 7 - 10, 01.03.2013

Ahmet Gürel Mustafa Metin Donma Burçin Nalbantoğlu Birol Topçu Zeynep Deniz Yıldız Feti Tülübaş

Abstract

Objective: We aimed to study if inhaled corticosteroid and inhaled beta 2 agonist treatment to2-18 years old children with asthma resulted in recovery in serum total IgE, CRP, and wholeblood count levels and/or to evaluate the effect of treatment in comparison to healthy children.Methods: Data regarding pre and post treatment serum total IgE, CRP, and hemogram levelsof 2-18 years old, 99 children with asthma, who received inhaled corticosteroid and inhaledbeta 2 agonist treatment and who applied to Namık Kemal University Research and PracticeHospital Pediatrics Clinic, were obtained through file scanning. Data regarding demographicsand serum total IgE, CRP and hemogram levels of 99 healthy children in control group werealso obtained through file scanning.Results: In children with asthma, levels of serum total IgE, lymphocyte, eosinophil and basophilcounts and percentages were significantly increased compared to healthy controls, and theywere significantly decreased after treatment to the levels of healthy controls. Serum CRP levels,neutrophil counts and percentages were significantly decreased compared to healthy controls,and they were significantly increased after treatment.Conclusions: Inhaled steroid and beta 2 antagonist treatment to children with asthma resultedin recovery in levels of IgE, CRP, and some whole blood count parameters through decreasinginflammation with its anti-inflammatory effect

Keywords

Asthma, IgE, CRP, hemogram

Astımlı Çocuklarda Tedavi Sonrası Total IgE, CRP ve Tam Kan Sayım Parametrelerinin Değerlendirilmesi

Abstract

Amaç: Bu çalışmada, astım tanısı alan 2-18 yaş arası çocuklara uygulanan inhale kortikosteroidve inhale beta 2 agonist tedavisinin serum total IgE, CRP ve tam kan sayım düzeylerindeiyileşme sağlayıp sağlamadığını ve/veya iyileşmenin derecesini sağlıklı çocukların düzeyleriile karşılaştırarak tedavinin etkisini araştırmayı amaçladık.Gereç ve Yöntem: Namık Kemal Üniversitesi Uygulama ve Araştırma Hastanesi çocuk sağlığıve hastalıkları polikliniğine müracaat eden 2-18 yaş arası astım tanısı almış ve inhalekortikosteroid ve inhale beta 2 agonist tedavisi görmüş 99 çocuğun tedavi öncesi ve tedavisonrası serum total IgE, CRP ve hemogram düzeyleri ile kontrol grubunu oluşturan 99 sağlıklıçocuğun serum total IgE, CRP ve hemogram düzeyleri ve demografik bilgileri dosya taramasıile elde edildi.Bulgular: Astımlı çocuklarda serum total IgE düzeyleri, lenfosit, eozinofil ve bazofil sayılarıve yüzdeleri sağlıklı kontrollere göre anlamlı olarak artarken tedavi sonrasında sağlıklıkontrollerin seviyesine gerileyerek anlamlı bir azalma göstermiştir. Serum CRP düzeyleri ilenötrofil sayısı ve yüzdeleri astımlı çocuklarda sağlıklı kontrollere göre anlamlı olarak azalırkentedavi sonrasında anlamlı artış meydan gelmiştir.Sonuç: Sonuç olarak astımlı çocuklara uygulanan inhale steroid ve beta 2 antagonist tedavisi,gösterdiği anti-inflamatuar etki sonucunda inflamasyonu azaltarak total IgE, CRP ve bazı tamkan sayım parametrelerinde iyileşme sağlamıştır

Keywords

Astım, IgE, CRP, hemogram

References

• Cohn L, Elias JA, Chupp GL. Asthma: mechanisms of disease persistence and progression. Annual review of immunology 2004; 22: 789-815.
• Kalyoncu AF. Bronş astması. 1. baskı. ed. Ankara: Atlas Matbaacılık; 2001.
• Garcia-Marcos L, Quiros AB, Hernandez GG, et al. Stabilization of asthma prevalence among adolescents and increase among schoolchildren (ISAAC phases I and III) in Spain. Allergy 2004; 59: 1301-7.
• Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary. The European respiratory journal: official journal of the European Society for Clinical Respiratory Physiology 2008; 31: 143-78.
• Hedlin G, Konradsen J, Bush A. An update on paediatric asthma. European respiratory review : an official journal of the European Respiratory Society 2012; 21: 175-85.
• Weiland SK, Husing A, Strachan DP, Rzehak P, Pearce N. Climate and the prevalence of symptoms of asthma, allergic rhinitis, and atopic eczema in children. Occupational and environmental medicine 2004; 61: 609-15.
• Pauwels RA, Pedersen S, Busse WW, et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet 2003; 361: 1071-6.
• Dursun F, Koç AN. Ig E, Eosinophil, CRP Levels and Atopy in the Asthmatic Children. Journal of Health Sciences 2007; 16: 80-5.
• Al-Daghri NM, Alokail MS, Abd-Alrahman SH, Draz HM, Yakout SM, Clerici M. Polycyclic aromatic hydrocarbon exposure and pediatric asthma in children: a case-control study. Environmental health : a global access science source 2013; 12: 1.
• Halisdemir N ÇC, Kutlu A, Öztürk S. Alerjik ve Alerjik Olmayan Astım Hastaları İçin Toplam Serum IGE Seviyesi Kesim Noktaları. FÜ Sağ Bil Tıp Derg 2009; 23 (2): 91 - 4.
• Pizzimenti S, Bussolino C, Badiu I, Rolla G. Itraconazole as 'bridge therapy' to anti-IgE in a patient with severe asthma with fungal sensitisation. BMJ case reports 2013; 2013.
• Ozgur ES, Ozge C, Ilvan A, Nayci SA. Assessment of Long- term Omalizumab Treatment in Patients with Severe Allergic Asthma. The Journal of asthma. 2013. doi: 10.1136/bcr-2012- 008462.
• Zietkowski Z, Tomasiak-Lozowska MM, Skiepko R, Mroczko B, Szmitkowski M, Bodzenta-Lukaszyk A. High- sensitivity C-reactive protein in the exhaled breath condensate and serum in stable and unstable asthma. Respiratory medicine 2009; 103: 379-85.
• Holgate ST, Polosa R. The mechanisms, diagnosis, and management of severe asthma in adults. Lancet 2006; 368: 780-93.
• Holgate ST, Djukanovic R, Casale T, Bousquet J. Anti- immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 2005; 35: 408-16.
• Adcock IM, Caramori G, Chung KF. New targets for drug development in asthma. Lancet 2008; 372: 1073-87.
• Kasayama S, Tanemura M, Koga M, Fujita K, Yamamoto H, Miyatake A. Asthma is an independent risk for elevation of plasma C-reactive protein levels. Clinica chimica acta; international journal of clinical chemistry 2009; 399: 79-82.
• Takemura M, Matsumoto H, Niimi A, et al. High sensitivity C-reactive protein in asthma. The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology 2006; 27: 908-12.
• Tülübaş F GA, Donma MM, Nalbantoğlu B, Topçu B, Mut ZD. Astma ve alerjik rinitli çocuklarda total IgE, C-reaktif protein ve kan sayım parametrelerinin değerlendirilmesi. Dicle Tıp Dergisi 2013; 40 57-61.
• To M, To Y, Yamada H, Ogawa C, Otomo M, Suzuki N, Sano Y. Influence of inhaled corticosteroids on community- acquired pneumonia in patients with bronchial asthma. Internal medicine (Tokyo, Japan) 2004; 43: 674-8.